We used Siltuximab — an FDA-approved anti-IL-6 mAb under the brand name of Sylvant for the treatment of patients with idiopathic multicentric Castleman’s disease (iMAD) — as a control (Figure 1A). The gene discussed is IL6; the disease is idiopathic multicentric Castleman disease.